3.26

2.52% +0.08

After Hours: 3.26

LENSAR Inc (LNSR)

Overview News Price History Option Chain Discussions Forecast

LENSAR Inc stock is currently priced at $3.26, with a 24-hour trading volume of 8,334. It has seen a +2.52% increased in the last 24 hours and a -7.12% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.19 pivot point. If it approaches the $3.29 resistance level, significant changes may occur.

Previous Close:

$3.18

Open:

$3.275

24h Volume:

8,334

Market Cap:

$37.15M

Revenue:

$42.16M

Net Income/Loss:

$-14.38M

P/E Ratio:

-1.7717

EPS:

-1.84

Net Cash Flow:

$-9.90M

1W Performance:

+6.54%

1M Performance:

-7.12%

6M Performance:

+49.54%

1Y Performance:

+26.36%

1D Range:

$3.13

$3.3262

52W Range:

$1.80

$5.30

LENSAR Inc Stock (LNSR) Company Profile

Name

LENSAR Inc

Sector

Healthcare (1198)

Industry

Medical Devices (158)

Phone

888 536 7271

Address

2800 Discovery Drive, Orlando

Employee

110

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

LNSR's Discussions on Twitter

LENSAR Inc Stock (LNSR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-21	Initiated	SVB Leerink	Outperform

LENSAR Inc Stock (LNSR) Financials Data

LENSAR Inc (LNSR) Revenue 2024

LNSR reported a revenue (TTM) of $42.16 million for the quarter ending December 31, 2023, a +19.25% rise year-over-year.

LENSAR Inc (LNSR) Net Income 2024

LNSR net income (TTM) was -$14.38 million for the quarter ending December 31, 2023, a +27.77% increase year-over-year.

LENSAR Inc (LNSR) Cash Flow 2024

LNSR recorded a free cash flow (TTM) of -$9.89 million for the quarter ending December 31, 2023, a +33.91% increase year-over-year.

LENSAR Inc (LNSR) Earnings per Share 2024

LNSR earnings per share (TTM) was -$1.79 for the quarter ending December 31, 2023, a +9.14% growth year-over-year.

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.